The clinical application of dp-vpa, a class 1 antiepileptic drug of Enhua Pharmaceutical Co., Ltd. has been completed

According to the information on April 13 on the website of CFDA, the clinical application status of dp-vpa APIs and tablets of class 1 new drug of Enhua Pharmaceutical Co., Ltd is shown as "certificate preparation completed - approved document issued in Jiangsu Province" According to the company, there should be no problem with the product being approved clinically, but the approval document should prevail "It should be announced after getting the approval." According to the public information, dp-vpa is a new antiepileptic drug based on VPA (valproic acid) Compared with valproic acid, dp-vpa showed better safety and pharmacokinetic characteristics in foreign experiments Enhua pharmaceutical pointed out that valproic acid preparation is the first-line drug for epilepsy treatment in China Although it has good efficacy, a series of adverse reactions limit the maximum dosage and wide use of valproic acid Dp-vpa will provide a safer and more efficient alternative to valproic acid In May 2011, Enhua pharmaceutical signed an agreement with d-pharm company of Israel on the exclusive license and cooperative development of dp-vpa for epilepsy treatment in China, and Enhua pharmaceutical exclusively carried out clinical research, registration, production and sales of dp-vpa for epilepsy treatment in China Enhua Pharmaceutical Co., Ltd is the leading drug manufacturer of central nervous system in China Its main products include three categories: anesthetics, psychotropic drugs and neurodrugs Psychotropic drugs, including dp-vpa, are the main direction of the company in the next stage It is expected that they will keep pace with or even surpass narcotic drugs in the future.